Home » Conference Report: Maintenance Is Not a Necessary Evil
Conference Report: Maintenance Is Not a Necessary Evil
PharmaManufacturing.com
03/09/2010
By Marc Laplante, Solution Specialist, Meridium, Inc.
Editor's Note: The following is special to PharmaManufacturing.com, courtesy of Mr. Laplante.
The theme of the conference, held February 22-24 in Philadelphia, was Operational Excellence. This was an intimate gathering of a very important group of professionals who are the substrate of Operational Excellence—Lean Six Sigma experts and practitioners.
The papers and keynotes presented methods on driving down costs, improving efficiencies, ensuring sustainability, augmenting quality, and deploying useful tactics on executing projects and strategies. The first module of the conference was called Reducing Operational Costs While Improving Efficiency. In this module, Meridium hosted a panel discussion on achieving sustainable improvement. The panel included Kim Palladino, Lean Six Sigma Master Black Belt from GlaxoSmithKline, Mr. Ed Kaercher, Facility and Project Management from PPD Vaccines and Biologics, and Mr. Paul Casto, Vice President and SME on Work Process Optimization from Meridium.
As panel moderator, I framed the discussion around “doing the right things and doing them right.” I noted that every delegate arrived at the conference hotel because of the stable running machines—cars, trains, planes—which had transported them there. I also pointed out that the comfortable environment they were sitting in—lighting, temperature, and hot coffee—was evidence of stable running machinery and that in fact, the critical importance of machinery reliability is often masked until the state of stable operation is interrupted.
The best performing companies recognize the importance of equipment reliability in their manufacturing processes and facilities. Reliability engineers are being brought into these organizations to identify and eliminate the defects leading to major failure incidents which add so much unnecessary cost to the business.
The panel also submitted to the delegates that maintenance is no longer a necessary evil. In fact, maintenance has grown into an essential part of Operational Excellence. Top performing companies question traditional maintenance practices and by doing so uncover a wealth of opportunities to release cash to the bottom line. Maintenance practitioners are no longer “firefighters”, but diagnosticians who are motivated by the stable running state of a machine. They are no longer motivated by the frenzied drive to fixing a machine that has unexpectedly halted production. Operators are also being brought in to participate in maintenance and reliability. Operators contribute to the state of stable running machinery because they have the “look, listen, and feel” perspective of the equipment. If something sounds or even smells different, you can bet an engaged operator is going to take notice.
The panel discussion revealed that there is a need for Pharmaceutical and Biotech manufacturers to add maintenance and reliability as a part of their schema for Operational Excellence. Without measureable asset performance, asset availability, and asset utilization, a state of predictable production cannot be reached. When the assets are not operating within a designed level of reliability (stable running equipment), how can Operational Excellence even be discussed? Lean Six Sigma experts and practitioners possess a perfect set of skills and training for leveraging this performance data into actionable intelligence. Mr. Casto stated that Lean Six Sigma is not a good fit for supporting reliability improvements, it is a perfect fit. Delegates expressed interest and appreciation for this topic during and after the panel discussion.
For more information on the conference, please contact the author at mlaplante@meridium.com.
More News:
-
02/09/2012
Watchdog Fines Ernst & Young $2 million Over Medicis Pharma Corp. AuditsFrom Reuters.com
The watchdog board for corporate auditors on Wednesday said it has imposed a $2 million penalty, its largest fine ever, on accounting and consulting firm Ernst & Young LLP in a settlement involving past audits of Medicis Pharmaceutical Corp.
-
02/09/2012
FDA Issues Draft Guidance on Biosimilar Product Development
The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.
-
02/08/2012
Biomedical Industry Loses Momentum in California, According to 2012 Report
Innovation slows as productivity in the Biomedical industry declines
-
02/02/2012
Pfizer Baby Boom? Pfizer's Official StatementFrom Pharmalot.com
About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Hear EVP and CMO, Freda Lewis-Hall's read Pfizer's official statement.
-
02/02/2012
News: AstraZeneca To Cut 7,300 JobsFrom MarketWatch.com
Drug firm AstraZeneca on Thursday said it would cut approximately 7,300 jobs as part of an ongoing initiative to reduce costs and drive innovation.
-
02/01/2012
Pfizer Recalls 1 Million Birth Control Packs for Error That Could Cause Unintended PregnancyFrom WashingtonPost.com
Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand.
-
01/26/2012
News: Abbott Labs Cuts 700 Manufacturing JobsFrom WashingtonPost.com
Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts. A company spokeswoman said most of the layoffs will affect employees who manufacture the company’s heart stents and diagnostic tests.
- 01/24/2012 ISPE Announces 2012 FOYA Winners
- 01/24/2012 Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
-
01/19/2012
Big Pharma Execs May Wish They'd Never Heard Of Paula DeenFrom Forbes.com
Novo Nordisk has nabbed Paula Deen as a new spokeswoman to help raise awareness about type 2 diabetes. Many in the drug industry wish it weren’t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east.
- All news »
Get Connected Now!
- Featured White Papers

Print page